Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
Total Valuation
Helix BioPharma has a market cap or net worth of C$183.31M. The enterprise value is C$0.00.
Market CapC$183.31M
Enterprise ValueC$0.00
Share Statistics
Helix BioPharma has 76,378,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding76,378,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Helix BioPharma’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -33.89%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-33.89%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-743.57K
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Helix BioPharma is ―. Helix BioPharma’s PEG ratio is 0.21.
PE Ratio―
PS Ratio0.00
PB Ratio3.83
Price to Fair Value3.83
Price to FCF-15.56
Price to Operating Cash Flow-40.84
PEG Ratio0.21
Income Statement
In the last 12 months, Helix BioPharma had revenue of 0.00 and earned -5.21M in profits. Earnings per share was -0.09.
Revenue0.00
Gross Profit-10.00K
Operating Income-5.42M
Pretax Income-5.23M
Net Income-5.21M
EBITDA-5.21M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -4.19M and capital expenditures -2.00K, giving a free cash flow of -4.19M billion.
Operating Cash Flow-4.19M
Free Cash Flow-4.19M
Free Cash Flow per Share-0.05
Dividends & Yields
Helix BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.37
52-Week Price Change166.67%
50-Day Moving Average2.25
200-Day Moving Average1.52
Relative Strength Index (RSI)55.14
Average Volume (3m)13.00K
Important Dates
Helix BioPharma upcoming earnings date is Mar 18, 2026, TBA (Confirmed).
Last Earnings DateDec 12, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Helix BioPharma as a current ratio of 0.13, with Debt / Equity ratio of 2.15%
Current Ratio0.13
Quick Ratio0.13
Debt to Market Cap<0.01
Net Debt to EBITDA-0.05
Interest Coverage Ratio-542.50
Taxes
In the past 12 months, Helix BioPharma has paid -28.00K in taxes.
Income Tax-28.00K
Effective Tax Rate<0.01
Enterprise Valuation
Helix BioPharma EV to EBITDA ratio is -11.49, with an EV/FCF ratio of -15.63.
EV to Sales0.00
EV to EBITDA-11.49
EV to Free Cash Flow-15.63
EV to Operating Cash Flow-15.64
Balance Sheet
Helix BioPharma has C$498.00K in cash and marketable securities with C$352.00K in debt, giving a net cash position of C$146.00K billion.
Cash & Marketable SecuritiesC$498.00K
Total DebtC$352.00K
Net CashC$146.00K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share-C$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Helix BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast59.00%